

#1770

COLUMBIA UNIVERSITY MEDICAL CENTER

BACKGROUND

Constitutively activated PI3K/AKT/mTOR pathway plays a critical role in the proliferation and survival of cancer cells, through the expression of numerous pro-survival and proliferative genes. Specific inhibitors of the various isoforms of PI3K have shown promising activity in the treatment of indolent B-cell lymphoma. However, they have not shown similar activity in aggressive lymphoma, potentially because the expression of many PI3K/AKT/mTOR dependent pro-survival genes may be activated by alternative signals. Notable examples of signals regulated by mTOR include the pro-survival NFkappaB (NF- κ B) pathway and the eukaryotic initiation factor 4F (eIF4F). Through a feed-forward loop, eIF4F controls the expression of c-Myc, a well established oncoprotein in many cancers including highly aggressive lymphoma.

Hypothesis

If both the proteasome and PI3K are involved in activation of mTOR, then combinations of proteasome and PI3K inhibitors will be able to potently inhibit the mTOR-eIF4F-Myc axis and kill Myc dependent cancer.





Table 1. Synergy of 4 different combinations of proteasome inhibitors and PI3K inhibitors. The LY10 cells were treated with the indicated compounds as single agent or in combinations, using a HTS platform. Synergy was indicated by values of Excess over Bliss (EOB) more than 10, with higher values of EOB indicating stronger synergy. The concentrations of the compounds were given on the X- and Y-axis, while the table included color coded EOB values.

Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma

CFZ-nM ⊡	TGR-μM	Effect	CI	RRR	Bort-nM	CAL-µM	Effect	CI	RRR	Table 2	Cal	Bort	Combo				TGF	Cfz	Combo		İ	
1	1	0.01	> 10	1.14	1	1	0	> 10	1.35		uM	nM	Effect	CI	RRR	EOB	uM	uМ	Effect	CI	RRR	
1.5	1	0.13	0.99	0.97	1.5	1	0	> 10	1.22		7.5											
2	1	0.43	0.67	0.75	2	1	0.09	2.33	1.28			7.5	0.1	0.91	0.93	7.3	7.5	7.5	0.21	0.82	0.96	
2.5	1	0.75	0.47	0.46	2.5	1	0.21	1.35	1.38	_	7.5	10.0	v .1	0.01	0.00	1.0		10.0	0.21	0.02	0.00	ĺ
	I									-		10.0	0.16	0.87	0.91	8.5	7.5	10.0	0.33	0.57	0.82	1
1	3	0.18	0.56	0.92	1	3	0.12	1.74	1.03	-	7.5	15.0	0.10	0.07	0.01	0.0		15.0	0.00	0.07	0.01	ſ
1.5	3	0.28	0.66	0.79	1.5	3	0.15	1.5	0.99	-	1.5	10.0	0.21	1.00	0.82	17.1	7.5	10.0	0.34	0.56	0.80	1
2	3	0.71	0.41	0.38	2	3	0.27	0.987	1.02	+	7.5	20.0	V.21	1.00	0.02	17.1		20.0	V.V-	0.00	0.00	t
2.5	3	0.92	0.27	0.14	2.5	3	0.35	0.9748	1.14	4	1.5	20.0	0.34	0.99	0.94	4.5	7.5	20.0	0.49	0.38	0.64	1
1	5	0.23	0.49	0.88	1	5	0.11	2.915	1.12	T I	10.0		0.04	0.33	0.94	4.0	10.0		0.45	0.00	0.04	
1.5	5	0.48	0.46	0.58	1.5	5	0.13	2.4119	1.10	•	10.0	7.5	0.19	0.78	0.84	9.0	10.0	7.5	0.31	0.80	0.84	
2	5	0.9	0.24	0.14	2	5	0.24	1.2	1.15		10.0		0.13	0.70	0.04	3.0	10.0	10.0	0.01	0.80	0.04	t
2.5	5	0.97	0.18	0.05	2.5	5	0.27	1.278	1.38	PF382	10.0	10.0	0.10	0.02	0.00	4.6	10.0	10.0	0.44	0.50	0.00	
	•		i						+ +	+ 	10.0	15.0	0.18	0.93	0.88	4.6	10.0	15.0	0.44	0.58	0.69	ł
CFZ-nM	TGR-μM	Effect	CI	RRR	Bort-nM	CAL-μM	Effect	CI	RRR	DND41	10.0	15.0	0.05	1 0 1	0.78	44.4	10.0	15.0	0.51	0.40	0.00	1
1	1	0.04	0.87	1.14	1	1	0.07	7.32	1.11	-	10.0		0.25	1.01	0.70	14.1	10.0	00.0	0.01	0.49	0.60	ł
1.5	1	0.38	0.51	0.97	1.5	1	0.13	1.30	1.07	-	10.0	~ ~		0.07	0.05	5.0	10.0	20.0		0.40	0.54	1
2	1	0.36	0.69	0.75	2	1	0.36	1.03	1.08	-		20.0	0.4	0.97	0.85	5.6	45.0	1	0.59	0.40	0.51	
2.5		0.55	0.68	0.46	2.5		0.67	0.86	1.06	_	15.0				0.77		15.0					
1	3	0.2	0.59	0.92	1	2	0.11	1.97	1.06		45.0	7.5	0.28	0.80	0.77	21.4	45.0		0.49	0.77	0.82	ł
1.5	3	0.65	0.36	0.79	1.5	3	0.16	1.19	1.00	-	15.0	10.0				40.0	15.0	10.0				1
2	3	0.63	0.49	0.38	2	3	0.38	1.01	1.05			45.0	0.3	0.87	0.79	18.8		45.0	0.58	0.62	0.68	ł
2.5	3	0.76	0.52	0.14	2.5	3	0.65	0.89	1.11		15.0	15.0					15.0	15.0				
													0.37	0.96	0.68	29.3			0.64	0.54	0.59	ł
1	5	0.17	0.53	0.88	1	5	0.15	1.00	1.05		15.0						15.0	20.0				
1.5	5	0.76	0.31	0.58	1.5	5	0.23	0.96	0.97	 		20	0.46	1.01	0.79	14.6			0.68	0.48	0.54	Ļ
2	5	0.81	0.38	0.14	2	5	0.36	1.03	1.10		Tal	ala 2	Cunora	nietie i	atoroati		V inhihi	tara a	ad prat		o inhihi	. ; 4
2.5	5	0.92	0.35	0.05	2.5	5	0.72	0.80	0.91	_							3K inhibi		•			
											acc	20200	d by 3 i	matha	de Tha	pancrea	atic coll l	ina Mi	a-Para	wae i	ncubate	(C

Table 2. Synergy of proteasome inhibitors and PI3K inhibitors. Two T-cell lymphoma cell lines, PF382 and DND41, were cultured and treated with the indicated compounds, as single agents or in combination. The fraction of growth inhibition (Effect) was shown for the combination treatments. Synergy was indicated by combination index (CI) or relative risk ratio (RRR) values below 1. CFZ: carfilzomib, TGR: TGR-1202, bort: bortezomib, CAL: CAL-101/idelalisib







Figure 4. Effects of proteasome and PI3K inhibitors on the mTOR-eIF4F-Mvc axis in DLBCL. Western blot was performed using the total protein extracts from LY10 cells treated by the indicated compounds as single agent or in combination for 24h. CFZ: carfilzomib, TGR: TGR-1202, bort: bortezomib, CAL: Cal-101/idelalisib. Samples were probed for proteins in the AKT-mTOR pathway (A), downstream signals regulated by mTOR (B), and eIF4F and its target proteins (C).

Changchun Deng¹, Mark Lipstein¹, Xavier Serrano¹, Michael Mangone¹, Luigi Scotto¹, Peter Sportelli², Hari P. Miskin², and Srikant Viswanadha³, Owen A. O'Connor¹ ¹Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY; ²TG Therapeutics, Inc., New York, NY; ³Incozen Therapeutics Pvt. Ltd., Hyderabad, India

RESULTS



agent or in combination for 24h. CFZ: carfilzomib, TGR: TGR-1202, bort: bortezomib, CAL: Cal-101/idelalisit Samples were probed for proteins in the AKT-mTOR pathway (A), downstream signals regulated by mTOR (B), eIF4F and its target proteins (C), and the NF-kB pathway (D). Note that nuclear extract was used in (D).